Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
12
01
2023
accepted:
27
01
2023
revised:
24
01
2023
medline:
11
9
2023
pubmed:
16
2
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Recently, Liau et al. reported the results of Phase 3 clinical trial testing DCVax-L vaccines on patients with glioblastoma. Despite the promising and significant results obtained, the study design and the long-lasting period of recruitment of this work deserve some reflection.
Identifiants
pubmed: 36792723
doi: 10.1038/s41416-023-02194-1
pii: 10.1038/s41416-023-02194-1
pmc: PMC10491746
doi:
Substances chimiques
Cancer Vaccines
0
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-896Informations de copyright
© 2023. The Author(s).
Références
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86.
doi: 10.1038/s41571-020-00447-z
pubmed: 33293629
Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20:1034–43.
doi: 10.1093/neuonc/noy027
pubmed: 29518210
pmcid: 6280141
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Yuan B, Wang G, Tang X, Tong A, Zhou L. Immunotherapy of glioblastoma: Recent advances and future prospects. Hum Vaccin Immunother. 2022;18:2055417.
doi: 10.1080/21645515.2022.2055417
pubmed: 35344682
pmcid: 9248956
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
doi: 10.1126/science.aar4060
pubmed: 29567705
pmcid: 7391259
Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, et al. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. Expert Rev Clin Immunol. 2016;12:1347–57.
doi: 10.1080/1744666X.2016.1202114
pubmed: 27323245
Adams AM, Vreeland TJ, Clifton GT, Peoples GE. ASO author reflections: the tumor lysate, particle-loaded, dendritic cell vaccine for advanced-stage melanoma: reflection on personalized cancer vaccination. Ann Surg Oncol. 2021;28:6138–9.
doi: 10.1245/s10434-021-09782-6
pubmed: 33638047
pmcid: 7909945
Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9:112–21.
Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, Singh H, Ibrahim A, DeClaro RA, et al. External control arms in oncology: current use and future directions. Ann Oncol. 2022;33:376–83.
doi: 10.1016/j.annonc.2021.12.015
pubmed: 35026413
Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–12.
doi: 10.4103/2229-3485.83221
pubmed: 21897887
pmcid: 3159210